Stocks

Regulus Therapeutics Finds No Adverse Findings in Halted RGLS4326 Trial

Regulus Therapeutics Finds No Adverse Findings in Halted RGLS4326 Trial

Regulus Therapeutics (RGLS) said on Friday the preliminary results of a planned interim data analysis from the new mouse chronic toxicity study of RGLS4326 in development for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD, found no adverse findings. “The planned interim analysis of this study after 13 […]